Table 2 Biochemical indicators and medication in the study groups

GA at diagnosis < 32 weeks,n(%)

59(16.2%)

47(9.4%)

.003^a

TBA (umol/L) at diagnosis,n(%)

.058

  ≥ 10, < 40

427(85.7%)

295(81%)

  ≥ 40, < 100

67 (13.5%)

62(17.0%)

  ≥ 100

6 (0.8%)

7 (2.0%)

ALT (U/L), median(P₂₅ ~ P₇₅)

140.0(60.0 ~ 241.5)

153.50(80.0 ~ 286.7)

.021^a

AST (U/L), median(P₂₅ ~ P₇₅)

102.00(51.0 ~ 185.0)

118.00(63.2 ~ 193.0)

.017^a

TBA Peak (umol/L), n(%)

.103

  ≥ 10, < 40

354(70.8%)

241(66.2%)

  ≥ 40, < 100

133(26.6%)

104(28.6%)

  ≥ 100

13 (2.6%)

19(5.2%)

TBA (umol/L) at delivery, n(%)

.211

  ≥ 10, < 40

434(86.8%)

305(83.8%)

  ≥ 40, < 100

59(11.8%)

52(14.3%)

  ≥ 100

7 (1.4%)

7(1.9%)

Medication of UDCA, n(%)

 Double-combinations

410(82%)

269(73.9%)

.075

 Triple-combinations

321(64.1%)

224(61.5%)

.588

Medication time(days), median(P₂₅ ~ P₇₅)

17.00(7.00 ~ 31.00)

17.00(7.00 ~ 33.00)

.816

Changing trend of TBA, n(%)

.926

 inefficacy

236(47.2%)

171(47.0%)

 improvement

152(30.4%)

115(31.6%)

 remission

112(22.4%)

78 (21.4%)